MyFinsight

HomeCompareAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Privacy Policy
  • Contact

Follow Us

  • Thread
  • X.com
  • Instagram

© 2026 MyFinsight. All rights reserved.

Recent SEC Filings
10/2NIKE, Inc.(NKE)10/2DARDEN RESTAURANTS INC(DRI)9/30CONAGRA BRANDS INC.(CAG)9/29Carnival Corp Ltd.(CCL)9/29URANIUM ENERGY CORP(UEC)9/29COPART INC(CPRT)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)10/2NIKE, Inc.(NKE)10/2DARDEN RESTAURANTS INC(DRI)9/30CONAGRA BRANDS INC.(CAG)9/29Carnival Corp Ltd.(CCL)9/29URANIUM ENERGY CORP(UEC)9/29COPART INC(CPRT)9/24BLACKBERRY Ltd(BB)9/24PAYCHEX INC(PAYX)9/23GENERAL MILLS INC(GIS)9/22ADOBE INC.(ADBE)9/18KROGER CO(KR)
||
||

Income Overview

Revenue
$398K
Net Income
-$28,919K
Net Profit Margin
-7266.08%
EPS
-$18.62
Unit: Thousand (K) dollars
Income Statement
2025-12-31
Collaboration revenue
398
Research and development
18,411
General and administrative
11,540
Restructuring and other related charges
1,469
Total operating expenses
31,420
Loss from operations
-31,022
Interest income
1,133
Other income
981
Total other income
2,114
Loss before income tax expense
-28,908
Income tax expense
11
Net loss
-28,919
Comprehensive loss
-28,919
Basic EPS
-18.62
Diluted EPS
-18.62
Basic Average Shares
1,553,473
Diluted Average Shares
1,553,473
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

LYRA Income Statement Sankey DiagramSankey diagram visualizing LYRA income statement for the periodComprehensive loss-$28,919K Net loss-$28,919K Interest income$1,133K Other income$981K Loss before incometax expense-$28,908K Income tax expense$11K Total other income$2,114K Loss from operations-$31,022K Collaboration revenue$398K Total operatingexpenses$31,420K Research and development$18,411K General andadministrative$11,540K Restructuring and otherrelated charges$1,469K

Lyra Therapeutics, Inc. (LYRA)

Lyra Therapeutics, Inc. (LYRA)